human nk-92 176v cells Search Results


no gfp cd16 nk 92 cell line  (ATCC)
93
ATCC no gfp cd16 nk 92 cell line

No Gfp Cd16 Nk 92 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+nk-92+176v+cells/Human+Natural+Killer+Cell+Line%3A%3B+NoGFP-CD16%2ENK92+%3B+NK-92+is+a+registered%3B+trademark+of+Nantkwest%2C+Inc/pmc08030737-57-0-7
Average 93 stars, based on 1 article reviews
no gfp cd16 nk 92 cell line - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
human nk-92 176v cells  (Conkwest Inc)
90
Conkwest Inc human nk-92 176v cells
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Human Nk 92 176v Cells, supplied by Conkwest Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+nk-92+176v+cells/nk+92+cell+line/pmc08953840-126-0-7
Average 90 stars, based on 1 article reviews
human nk-92 176v cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cd16 176 v nk 92 cell line  (ATCC)
99
ATCC cd16 176 v nk 92 cell line
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Cd16 176 V Nk 92 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+nk-92+176v+cells/NK-92/pmc09013517-68-10-14
Average 99 stars, based on 1 article reviews
cd16 176 v nk 92 cell line - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
nk92 gfp cd16 176v cell lines  (ATCC)
99
ATCC nk92 gfp cd16 176v cell lines
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Nk92 Gfp Cd16 176v Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+nk-92+176v+cells/293T/pmc11336212-317-2-9
Average 99 stars, based on 1 article reviews
nk92 gfp cd16 176v cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
nk-92-cd16 cells  (NantKwest)
90
NantKwest nk-92-cd16 cells
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Nk 92 Cd16 Cells, supplied by NantKwest, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+nk-92+176v+cells/nk+92+cells/10__1128_slash_jvi__00411___17-163-0-28
Average 90 stars, based on 1 article reviews
nk-92-cd16 cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human recombinant il-2  (GenScript corporation)
90
GenScript corporation human recombinant il-2
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Human Recombinant Il 2, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+nk-92+176v+cells/il+2+cytokine/10__1074_slash_jbc__m112__344325-47-59-61
Average 90 stars, based on 1 article reviews
human recombinant il-2 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Journal: Med (New York, N.y.)

Article Title: Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

doi: 10.1016/j.medj.2021.04.003

Figure Lengend Snippet:

Article Snippet: No-GFP-CD16.NK-92 cell line (High affinity 176V) , ATCC , PTA-6967.

Techniques: Virus, Recombinant, Staining, Luminex, Neutralization, Generated, Software

(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo

doi: 10.1158/1078-0432.CCR-17-1193

Figure Lengend Snippet: (A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Article Snippet: Human NK-92 176V cells were obtained from Conkwest Inc. (San Diego, CA).

Techniques: Imaging, Luciferase, Expressing